Home hero image

demonstrates 3 years (144 weeks) durable efficacy1

Through pooled data from the Cimzia arms of CIMPASI 1 and 2 trials (patients with moderate to severe plaque psoriasis).2

Cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Why Cimzia image

Why is CIMZIA® different?

 

Cimzia is a PEGylated, FC free anti-TNF.1

 

 

 

Why is CIMZIA® different?
efficacy teaser image

CIMZIA’s durable efficacy and long term safety profile in plaque psoriasis

With 10+ years’ experience since approval across multiple indications.1

 

 

Efficacy & Safety
Teaser future prof

Safety profile

 

Cimzia® (certolizumab pegol) has a well-established, long-term safety profile across Axial spondyloarthritis (axSpA), Plaque psoriasis (PsO), Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA).1

 

 

 

Safety Information
alt

Making treatment choices for your female psoriasis patients of childbearing age

 

 

Discover why CIMZIA® could be a suitable treatment choice for your eligible female moderate to severe plaque psoriasis patients.1

Female Patients
alt

CRIB study & CRADLE Studies

 

CRIB was a prospective postmarketing multicentre pharmacokinetic study designed to detect any placental transfer of Cimzia (CZP) from mothers to infants.4

 

CRADLE was the first industry-sponsored clinical study to evaluate Cimzia concentrations in human breast milk.3 

More information
Why Cimzia image

Dosing and administration

Cimzia maintenance dosing regimen is preceded by a loading dose across all indications1

 

 

 

 

 

 

 

See Dosing Guide
DERM WOBCA factsheet Icon.png

 

Patient Support
CIMZIA® (certolizumab pegol) in pregnancy and breastfeeding


This factsheet aims to provide information about the exposure to CIMZIA during pregnancy and breastfeeding, to aid your clinical practice and help you advise your patients.
 

Download

References

 

  1. CIMZIA® Summary of Product Characteristics.
  2. Gottlieb AB, et al. J Am Acad Dermatol. 2018;79(2):302-314
  3. Clowse MEB, et al. Ann Rheum Dis 2017;76(11) 1890-1896.
  4. Mariette X, et al. Annals of the Rheumatic Diseases 2018;77:228-233.

 

Date of preparation: April 2025

IE-CZ-2300025

© UCB Biopharma SRL, 2021. All rights reserved.

Logo footer